Exchange: NASDAQ·Updated 07:06 PM EDT
HUMA logo

HUMAHumacyte Inc

$0.67
$0.0146
(2.23%)
Today
Closed $0.6708
$0.0008
(0.12%)
After Hours
EarningsAug 10
Mkt Cap$176.94M
Vol8.63M
News
all
press releases
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
Humacyte, Inc. (HUMA) closed at $0.66 in the latest trading session, marking a -1.28% move from the prior day.
Zacks
More News
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
Humacyte, Inc. (HUMA) closed the most recent trading day at $0.71, moving +2.31% from the previous trading session.
Zacks
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $20.3 million. Humacyte (NASDAQ:HUMA) shares moved upwards by 5.45% to $0.71.read more...
Benzinga
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.78, representing a -2.32% change from its previous close.
Zacks
Here's Why Humacyte, Inc. (HUMA) Fell More Than Broader Market
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.62, signifying a -11.14% move from its prior day's close.
Zacks
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet
The average brokerage recommendation (ABR) for Humacyte, Inc. (HUMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Zacks
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know
Humacyte, Inc. (HUMA) closed the most recent trading day at $1.03, moving 3.74% from the previous trading session.
Zacks
Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know
Humacyte, Inc. (HUMA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
HUMA Stock Plunges After-Hours On Proposed Share Offering Even As Dialysis Data Impresses
The size and price of the stock offering were not disclosed.
Stocktwits
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, June 5, 2026 Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We...
PR Newswire
<
1
2
...
>

Advertisement|Remove ads.